




EMLc
Codes ATC: **A07AA06**

Indication	Visceral leishmaniasis Code ICD11: 1F54.0
INN	Paromomycin
Type de médicament	Chemical agent
Type de liste	Liste de base (EML) (EMLc)
Formulations	Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)
Historique des statuts LME	Ajouté pour la première fois en 2007 (TRS 946) Modifié en 2007 (TRS 950)
Sexe	Tous
Âge	Aussi recommandé pour les enfants
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets. 
Wikipédia	Paromomycin 
DrugBank	Paromomycin 

Résumé des preuves et recommandation du comité d'experts

Paromomycin was considered at the 15th Expert Committee meeting in March 2007, where paromomycin solution for intramuscular (IM) injection was added to the Model List. The Expert Committee concluded that paromomycin was effective in terms of effect on standard endpoints, such as initial and final cure, for the treatment of visceral leishmaniasis in children and adults. Paromomycin is licensed in India, and was granted orphan drug designation by the US Food and Drug Administration (FDA) in March 2005 and the European Medicines Agency (EMA) in April 2005. The EMLc Subcommittee endorsed the listing of paromomycin IM injection on the first EMLc.

